(Q46146766)

English

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta

scientific article published in March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

1 reference

based on heuristic

inferred from title

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mar Garcia

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

Jorge E Romaguera

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

Kedar V Inamdar

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

George Z Rassidakis

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

L Jeffrey Medeiros

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

language of work or name

0 references

publication date

1 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

115

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

1041-1048

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of mantle cell lymphoma: current approach and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Current management of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Mantle cell lymphoma: advances in biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Mantle-cell lymphoma: a population-based clinical study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24141

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24141

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19170236

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46146766&oldid=2130358009"